The US-American Alzheimer’s Association is a non-profit organization dedicated to pro- mote support and research on Alzheimer’s disease. To raise awareness and show that Alzheimer’s affects everybody, at least financially, the cost for businesses and the health care system are related to the dividends that investment into Alzheimer’s research implies.
Alzheimer’s medication delays the outbreak of the disease and slows progression of the medical conditions of Alzheimer’s and other dementias. Assuming that research leads to more powerful medications, investment into this research would generate savings of up to US$88 billion in 2020 and around US$440 billion in 2050.
The average payment per beneficiary, aged 65 years or older, with Alzheimer’s disease or other dementias summed up to US$33 billion. In comparison, disbursement for other policy holders in the same age group amounts US$ 10.6 billion (2004) The total cost of
Alzheimer’s for US companies equaled $61 billion in 2002. Of this amount, 55% are related to the cost of Alzheimer’s caregivers and around 40% are related to the companies’ contribution to healthcare .
Tagged as Alzheimer's disease
